Find participating medical centers and current study status in each of them

    Find participating medical centers

    A study to compare standard treatment plus inavolisib or a non-active placebo in people with PIK3CA-mutated, hormone receptor-positive, HER2-negative breast cancer that has spread in the body

    A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

    • Cancer
    • Breast Cancer
    • Breast Cancer Er-Positive
    • HER2-Positive Breast Cancer